Cirmtuzumab

Cirmtuzumab is an experimental medicine designed to treat certain blood cancers, such as leukemia and lymphoma. It works by targeting a specific protein called ROR1 found on cancer cells, helping the immune system recognize and attack these cells more effectively. By blocking ROR1, cirmtuzumab aims to slow or stop the growth of cancer without harming normal cells. It is still under research and not yet widely available, but it offers promising hope for patients with limited treatment options.